Parabilis Medicines
PBLS
28.82
-0.04
-0.14%
Parabilis Medicines
US · PBLS
#2366 by market cap
Listed 2026
28.82
-0.04
-0.14%
Live - 5344 symbols - heartbeat 77s ago
· 2026-10-08 08:24
Pre-market
28.50
-1.11%
After-hours
28.82
0.00%
- Market cap
- 3.56B
- P/E (TTM)i
- -15.17
- P/Bi
- 3.40
- EPSi
- -1.82
- Div yieldi
- 0.00%
- 52W posi
- 24%
Reader sentiment
Are you bullish or bearish on PBLS?
Anonymous reader poll. Unscientific, not investment advice.
About Parabilis Medicines
Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize them. The company was founded by Gregory L. Verdine, WeiQing Zhou and David Philip Lane in 2015 and is headquartered in Cambridge, MA.
- Founded
- 2015
- CEO
- Dr. Mathai Mammen, M.D.,PhD
- Employees
- 176
- Headquarters
- Cambridge, Massachusetts, United States of America
- Fiscal year end
- 12-31
- Website
- parabilismed.com
Company profile
- Exchange
- US
- Symbol
- PBLS
- Market-cap rank
- #2366
- Listing date
- 2026-06-10
- Market cap
- 3.56B
- Float cap
- 965.47M
- Shares out
- 123.53M
- Float shares
- 33.50M
Sectors & themes
Biotechnology
IPOs
Quote time 2026-10-08 08:24:43 · For reference only, not investment advice and not tailored to your situation.